Targeted Therapy Market - Strategic Insights and Forecasts (2026-2031)

The targeted therapy market is set to reach USD 170.2 billion in 2031, growing at a CAGR of 7.6% from USD 118.2 billion in 2026.

Asia-Pacific is the fastest-growing regional market due to rising cancer incidence, expanding healthcare infrastructure, increasing healthcare expenditure, growing adoption of precision medicine, and significant investments in oncology research across countries such as China, India, and Japan.

Key Highlights

• Precision oncology drives targeted therapy adoption by matching treatments to specific genetic mutations and biomarkers in tumors, enabling more effective and less toxic cancer care options.

• Antibody-drug conjugates and bispecific antibodies represent major innovations, delivering potent payloads directly to cancer cells while enhancing immune system engagement against malignancies.

• Expanding biomarker testing and companion diagnostics facilitate personalized treatment selection, improving patient outcomes across various cancer types, including lung, breast, and colorectal.

• Combination strategies with immunotherapies and next-generation inhibitors address resistance mechanisms, broadening the clinical impact of targeted therapies in refractory and advanced diseases.

Market Dynamics

Drivers

• Growing Investment in Oncology Research and Drug Development

One of the key factors driving the global targeted therapy market’s growth is increasing investment in oncology research and drug development. This not only results in more discovery but also rapidly brings new precision medicines to the market. Pharma and biotech firms are raising their R&D budgets to unveil the new molecular targets, genetic mutations and pathways involved in cancer development. The development of genomics, proteomics, and bioinformatics has enabled scientists to create highly precise therapies that specifically attack cancer cells and cause less harm to normal cells.

• The Ministry of Health and Family Welfare (MOHFW) has been given a total of Rs. 99,858.56 crore, with Rs. 95,957.87 crore earmarked for the Department of Health and Family Welfare and Rs. 3,900.69 crore for the Department of Health Research.

• The Indian government has an ambitious plan to set up Day Care Cancer Centres throughout all district hospitals within the next three years, and 200 centres are expected to be established in 2025-26.

• To reduce the cost of treatment, a complete exemption from Basic Customs Duty (BCD) has been granted to 36 lifesaving drugs and medicines that are used for the treatment of cancer, rare diseases and chronic diseases.

• Moreover, more cooperation between pharmaceutical companies, academic research institutions, contract research organizations, and healthcare providers is contributing to greater innovation and faster development timelines.

• Eli Lilly and Company revealed that it has acquired Scorpion Therapeutics' investigational PI3K inhibitor STX-478 in a transaction the total potential value of which was set at $2.5 billion, based on a high level of attraction for precision oncology as well as targeted cancer treatment assets within the industry.

• Advancements in Molecular Diagnostics: The evolution of genomic and biomarker testing has significantly enhanced the identification of actionable mutations. This enables precise patient selection, improving treatment outcomes and reducing unnecessary drug exposure. As diagnostic capabilities expand, the addressable patient population for targeted therapies continues to grow.

• Increasing Prevalence of Cancer with Defined Biomarkers: The rising incidence of cancers associated with specific genetic mutations is driving demand for targeted therapies. Conditions such as lung cancer and melanoma increasingly rely on biomarker-driven treatments, making targeted therapy a preferred option in many clinical settings.

• Favourable Clinical Outcomes and Reduced Toxicity: Targeted therapies offer superior efficacy and a more favorable safety profile compared to traditional chemotherapy. Reduced off-target effects lead to better patient compliance and quality of life, which is a critical factor in long-term cancer management.

Restraints and Opportunities

• High cost of targeted therapies limits accessibility, particularly in low- and middle-income regions.

• Development of resistance to targeted agents reduces long-term treatment effectiveness.

• Stringent regulatory requirements and lengthy approval timelines delay market entry.

• Expansion of Combination Therapy Approaches: Combining targeted therapies with immunotherapy or chemotherapy is showing enhanced efficacy across multiple cancer types. These approaches improve survival rates and expand the applicability of targeted treatments, creating significant growth opportunities.

• Emergence of Next-Generation Targeted Agents: Advancements in drug design are leading to the development of next-generation inhibitors with improved specificity and reduced resistance. These innovations address existing limitations and extend the lifecycle of targeted therapies.

• Growth in Emerging Markets: Improving healthcare infrastructure and increasing awareness of precision medicine are driving adoption in emerging regions. As diagnostic capabilities improve, demand for targeted therapies is expected to rise significantly.

• Integration of Artificial Intelligence in Drug Discovery: AI-driven platforms are accelerating the identification of novel drug targets and optimizing clinical trial design. This reduces development timelines and enhances the success rate of targeted therapy candidates.

Supply Chain Analysis

The targeted therapy supply chain depends on high-precision manufacturing processes involving biologics and complex chemical synthesis. Demand variability is increasing as personalized treatment approaches require smaller, patient-specific production volumes. Raw material sourcing constraints affect biologics manufacturing, particularly for monoclonal antibodies requiring specialized inputs. Companies are expanding production capabilities to meet growing demand while maintaining regulatory compliance. Distribution networks are evolving to support temperature-sensitive products and specialized handling requirements. This supply chain complexity necessitates advanced coordination to ensure consistent availability.

Government Regulations

Key Developments

• March 2026: Pfizer Inc. reported positive clinical trial results for its chemotherapy-based combination regimen in metastatic breast cancer, demonstrating improved therapeutic response and disease control compared to standard treatment approaches. This development reinforces the continued relevance of combination chemotherapy strategies, supporting their role alongside emerging targeted therapies and sustaining demand within the chemotherapy market.

• March 2026: Novartis acquired an experimental PI3K inhibitor (SNV4818) in 2026 to strengthen its targeted therapy portfolio in breast cancer, which reflects increasing demand for mutation-specific inhibitors with improved safety profiles.

• January 2026: AstraZeneca acquired Modella AI in 2026 to integrate artificial intelligence into oncology research, which is enhancing biomarker identification and accelerating the development of targeted therapies.

• 2026: Merck & Co., Inc. announced that the U.S. FDA granted Breakthrough Therapy Designation to calderasib (MK-1084), an investigational KRAS G12C inhibitor, in combination with Keytruda for the first-line treatment of certain patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC).

• March 2025: The U.S. Food and Drug Administration approval of Pluvicto from Novartis for use before chemotherapy marks a clear shift in oncology treatment sequencing. In March 2025, the label was expanded to include patients with PSMA-positive metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitor therapy, allowing clinicians to delay taxane-based chemotherapy.

Market Segmentation

By Therapy Type

Targeted therapy demand varies by mechanism of action, where monoclonal antibodies dominate due to high specificity in targeting tumor antigens. Demand is shifting toward small-molecule inhibitors as oral administration improves patient convenience. Resistance development limits the long-term efficacy of certain therapies, which drives innovation in next-generation inhibitors. Pharmaceutical companies are expanding portfolios to address multiple pathways simultaneously. This segmentation reflects mechanism-driven demand shaping treatment selection.

By Indication Type: Breast Cancer

By Indication type, the targeted therapy market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, lymphoma, and others. Lung and breast cancer are amongst the common cancer types, with high prevalence, which will drive targeted therapy development for treating such cancer types.

Ongoing gene mutation has improved cancer progression, thereby demanding a more robust and effective alternative for treatment. The breast cancer segment is expected to show considerable growth, fueled by the growing high prevalence and hormonal influences in females.

• Being one of the common cancer types reported globally, with annual prevalence reaching in millions according to WHO, the expanding patient strength is demanding better treatment options, especially for HER2-positive/negative and TNBC (Triple Negative Breast Cancer)

• Pharmaceutical giants like Pfizer Inc., showcasing positive results in their Phase-2 study of atirmociclib as a next-generation cell-cycle inhibitor for HR positive, HER2-breast cancer, have further bolstered the development strategy for targeted therapies.

• Regulatory programs like the FDA’s “Accelerated Approval” and “Breakthrough Therapy Designation (BTD)” that improve the development and access of drugs targeting life-threatening diseases are set to drive the market trajectory.

• Ongoing advancement in precision medicine has led to new approvals, like FDA approval of “Enhertu” as a first-line treatment for HER2-positive breast cancer, which is further enhancing the treatment scenario.

• The International Agency for Research on Center indicates that the global incidence of cancer is expected to increase from 2.5 million in 2025 to 2.7 million by 2030, with projections reaching up to 2.9 million by 2035. This rise reflects the economic burden of the disease, highlighting the urgent need for effective treatment alternatives and a better understanding of its genomic underpinnings.

By Route of Administration

Intravenous administration remains dominant due to biologic drug requirements and controlled dosing. Demand is shifting toward oral therapies as patients seek convenience and reduced hospital dependency. Bioavailability challenges constrain oral drug development, which limits widespread adoption. Companies are investing in formulation improvements to enhance absorption. This transition gradually diversifies administration methods while maintaining clinical reliability.

Regional Analysis

North America Market Analysis

North America is the leading region in the targeted therapy market because of advanced health care systems, strong R&D capabilities, and early adoption of innovative therapies. The high incidence of cancer and favourable reimbursement policy are also major contributing factors to North America's dominance within the market.

Demand Drivers

• Ongoing advancement in diagnostics and molecular profiling, followed by regulatory support to improve treatment options for cancer, especially for the aging population, is driving regional market expansion.

• Approval of immune-therapies to treat aggressive cancer has amplified market growth. For instance, in October 2025, Canada-based Apotex Inc. received NOC for its “LOQTORZI” for treating NPC (Nasopharyngeal Carcinoma).

• With research studies showcasing a constant progression in cancer mortality in North America further outlines the critical need for developing advanced treatment options.

Regulatory Overview

• Regulatory guidelines established by governmental bodies like the U.S. Food and Drug Administration (FDA) to support new drug development and improve their access via AA (Accelerated Approval) pathways define the market scenario for targeted therapies.

• Other regional nations like Canada are emphasizing their companion diagnostics framework via CTA programs, while primary health regulators like the Federal Commission for the Protection Against Sanitary Risks (COFEPRIS) have established a stringent framework in Mexico for the development of drugs related to cancer.

The US

Epidemiology

• The aging population and ongoing hormonal and lifestyle imbalance increased cancer prevalence in Americans, with data provided by the American Cancer Society indicating that the estimated number of new cancer cases is expected to reach up to 2,114,850 in 2026, with total death count reaching 626,140. Strategic efforts

• Well-established presence of global players like Pfizer Inc, AstraZeneca, Roch Ltd. and Eli Lilly and Company, among others, which are showcasing investment in new drugs and oncology therapies, has transformed the overall market landscape.

• Ongoing FDA approvals of various targeted drugs like “Capivasertib” for treating specific cancer types such as metastatic breast cancer, and “HERNEXEOS” for treating non-small lung cancer are set to drive further innovations in targeted therapy.

• Strong investment in an innovative pipeline, followed by transition towards current biotech trends for better outcomes, is set to pave the way for future market expansion in the United States.

Regulatory Framework

• The Expedited Approval Programs by the FDA promote and review the therapies that address the unmet medical needs during cancer treatment. Accelerated Approval (AA) is a key part of such programs and promotes consistency in clinical trials.

• Establishment of initiatives like “Precision Medicine Initiative (PMI)” followed by implementation of pediatric-centric regulations such as the FDA Reauthorization Act (FDARA) further outlines the essence of the study of molecular targeted oncology drugs, thereby further enabling clinical developments.

Europe Market Analysis

The European market is sizeable, with steady growth driven by the increasing uptake of precision medicine and its supportive regulatory framework. The ongoing investment in oncology research and cross-border collaboration are expected to drive the growth of this market further.

Asia Pacific Market Analysis

Asia Pacific is the fastest growing region. The large number of cancer patients, the increased incidence rates of cancer, and improved access to advanced diagnostics are all contributing factors to the rapid growth of this market. An increase in health care expenditures has also allowed for an increase in the uptake of targeted therapies.

Rest of the World

The rest of the world region is experiencing a slow but steady growth in the target therapy market; improvements in health care infrastructure and increasing access to cancer treatments are driving this growth, while cost constraints remain barriers. However, targeted therapies continue to gain market traction in a select number of markets.

Regulatory Landscape

Each targeted therapy has very stringent regulatory requirements due to the complexity and precision of these therapies. The regulatory agencies require a number of different clinical data that support the safety and efficacy of the therapies and the specificity of the biomarker. In situations where targeted therapies are used to treat unmet medical needs (especially for oncology therapies), accelerated approval processes have typically been used, which allow for more rapid access for patients, while still maintaining the highest standard of evaluation.

Companion diagnostics play an essential role in the regulatory approval processes. Companion diagnostics are critical in the identification of patient populations that are eligible for the corresponding targeted therapies. Therefore, the regulatory body must simultaneously approve both the therapeutics and diagnostic components of the companion diagnostic product. An increased emphasis on real-world evidence and post-marketing data collection has also been established by regulatory bodies, with the intention of monitoring the long-term safety of targeted therapies.

Pipeline Analysis

The chemotherapy pipeline remains active, with numerous candidates in various stages of development. Current data indicate that over 200 chemotherapy-related compounds are under investigation globally, with a significant proportion focused on improving drug delivery and reducing toxicity. Many pipeline candidates are reformulations of existing drugs, leveraging advanced technologies such as liposomal encapsulation and targeted delivery systems.

Late-stage clinical trials are increasingly focused on combination therapies, integrating chemotherapy with immunotherapy or targeted agents. This trend reflects the evolving role of chemotherapy as part of multi-modal treatment strategies. Additionally, there is growing interest in developing oral chemotherapy agents, which account for a notable share of pipeline activity. These developments are expected to enhance patient convenience and expand treatment accessibility.

Competitive Landscape

• F. Hoffmann-La Roche Ltd.

• Novartis AG

• Pfizer Inc.

• AstraZeneca plc

• Bristol Myers Squibb Company

• Eli Lilly and Company

• Amgen Inc.

• Merck & Co., Inc.

• Sanofi S.A.

• Gilead Sciences, Inc.

Company Profiles

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. maintains leadership through its strong portfolio of monoclonal antibodies and targeted oncology drugs, supported by extensive research capabilities.

Pfizer Inc.

Pfizer Inc. leverages its diversified oncology pipeline and global reach to strengthen its position in targeted therapies across multiple indications.

Novartis AG

Novartis AG focuses on innovative targeted treatments and precision medicine approaches, enhancing its competitive edge in oncology.

Merck & Co., Inc.

Merck & Co., Inc., is a significant participant in the targeted therapy market through its Healthcare business, focusing on the development and commercialization of precision medicines for oncology and other specialty disease areas. The company leverages its strong research capabilities in molecular biology, biomarker discovery, and translational medicine to develop targeted treatments that address specific genetic mutations and disease pathways. Merck's targeted therapy portfolio includes therapies designed to improve treatment outcomes by selectively acting on cancer cells while minimizing damage to healthy tissues.

Bristol-Myers Squibb

Bristol-Myers Squibb Company emphasises synergistic treatment approaches, combining targeted agents with immunotherapies to improve outcomes.

Strategic Insights and Future Market Outlook

The targeted therapy market is entering a phase of accelerated innovation, driven by advances in genomics, biomarker identification, and drug design. Companies are increasingly focusing on developing highly specific agents that address resistance mechanisms and improve long-term outcomes. This strategic shift is essential for sustaining growth in a competitive and rapidly evolving oncology landscape.

Future growth will be heavily influenced by the integration of targeted therapies into combination treatment regimens. These approaches not only enhance efficacy but also broaden the applicability of targeted treatments across diverse patient populations. Additionally, the expansion of companion diagnostics will play a crucial role in ensuring precise patient selection and maximising therapeutic benefits.

The market is expected to witness continued expansion, particularly in emerging regions where healthcare infrastructure is improving. However, cost considerations and access disparities will remain key challenges. Strategic collaborations, pricing innovations, and regulatory support will be critical in addressing these issues and unlocking the full potential of targeted therapies.

The targeted therapy market represents a transformative shift in oncology, redefining treatment paradigms through precision medicine, and its continued evolution will play a pivotal role in improving cancer outcomes globally.

Targeted Therapy Market Scope: